Supplementary management of chronic Lyme disease with Pycnogenol®
In conclusion, the present registry study showed that Pycnogenol<sup>®</sup> intake for 6 months in patients with persistent symptoms of Lyme disease can help relieve the main symptoms by reducing inflammation and oxidative stress. Pycnogenol's anti-inflammatory and antioxidant double activity may help safely and effectively controlling the chronic inflammatory process.
Authors
- Beatrice Feragalli (ORCID: https://orcid.org/0000-0002-6222-024X)
- Ezio Bombardelli
- Roberto COTELLESE
- Gianni Belcaro (ORCID: https://orcid.org/0000-0001-9566-6793)
- P. Bavera (ORCID: https://orcid.org/0000-0002-4520-9129)
- Lars Rosenkvist
- Umberto CORNELLI
- Valeria SCIPIONE
- Claudia SCIPIONE
- Giovanni B. Agus
- M R Cesarone
- Francesca Coppazuccari
- Hu Shu (ORCID: https://orcid.org/0000-0002-2809-8228)
- Marcello Corsi
- Morio Hosoi
Institutions
- Sygehus Sønderjylland (DK)
Publication Details
- Journal
- Minerva Medica
- Published
- 2025-05-15
- DOI
- https://doi.org/10.23736/s0026-4806.25.09703-4
- Primary Topic
- Vector-borne infectious diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00